Literature DB >> 3443142

Propranolol steady-state pharmacokinetics are unaltered by omeprazole.

D Henry1, P Brent, I Whyte, G Mihaly, S Devenish-Meares.   

Abstract

In a randomised double-blind cross-over study, 8 normal subjects received propranolol 80 mg twice daily with omeprazole 20 mg or identical placebo each morning. Propranolol kinetics were measured on day 8 of both treatment periods. Areas under the propranolol concentration/time curves were not significantly increased by omeprazole treatment: off treatment mean 787.6, on treatment 802.5 ng-1.ml.h. Maximum and minimum steady-state propranolol concentrations were similarily unaffected. Omeprazole also failed to increase the clinical effect of propranolol, as assessed by exercise tests on Day 8 of treatment. We conclude that omeprazole in the dose likely to be used for peptic ulcer has no significant effect on the kinetics or action of propranolol.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3443142     DOI: 10.1007/BF00637632

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Exercise testing of patients with coronary heart disease. Principles and normal standards for evaluation.

Authors:  R A Bruce
Journal:  Ann Clin Res       Date:  1971-12

2.  Inhibition by omeprazole of adrenocortical response to ACTH: clinical studies and experiments on bovine adrenal cortex in vitro.

Authors:  C W Howden; C J Kenyon; G H Beastall; J L Reid
Journal:  Clin Sci (Lond)       Date:  1986-01       Impact factor: 6.124

3.  Omeprazole in duodenal ulceration: acid inhibition, symptom relief, endoscopic healing, and recurrence. Cooperative study.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-01

4.  Omeprazole: effects on oxidative drug metabolism in the rat.

Authors:  D A Henry; J F Gerkens; P J Brent; P J Dosen
Journal:  Clin Exp Pharmacol Physiol       Date:  1986-05       Impact factor: 2.557

5.  Effect of omeprazole and polyethylene glycol-400 on antipyrine elimination by the isolated perfused rat liver.

Authors:  L K Webster; D B Jones; G W Mihaly; R A Smallwood
Journal:  J Pharm Pharmacol       Date:  1984-07       Impact factor: 3.765

6.  Simultaneous high-performance liquid chromatographic analysis of omeprazole and its sulphone and sulphide metabolites in human plasma and urine.

Authors:  G W Mihaly; P J Prichard; R A Smallwood; N D Yeomans; W J Louis
Journal:  J Chromatogr       Date:  1983-12-09

7.  Omeprazole: effects on oxidative drug metabolism.

Authors:  D A Henry; K W Somerville; G Kitchingman; M J Langman
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

8.  Propranolol, propranolol glucuronide, and naphthoxylactic acid in breast milk and plasma.

Authors:  M T Smith; I Livingstone; W D Hooper; M J Eadie; E J Triggs
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

9.  Inhibition of human liver cytochrome P-450 by omeprazole.

Authors:  J C Jensen; R Gugler
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

10.  Cimetidine increases steady state plasma levels of propranolol.

Authors:  I W Reimann; U Klotz; B Siems; J Frölich
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

View more
  24 in total

1.  Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol.

Authors:  T Andersson; P Lundborg; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects.

Authors:  P A Soons; G van den Berg; M Danhof; P van Brummelen; J B Jansen; C B Lamers; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers.

Authors:  K A Jönsson; A W Jones; H Boström; T Andersson
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 4.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

5.  Theophylline steady state pharmacokinetics is not altered by omeprazole.

Authors:  A M Taburet; J Geneve; M Bocquentin; G Simoneau; C Caulin; E Singlas
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 7.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

8.  Utilizing In Vitro Dissolution-Permeation Chamber for the Quantitative Prediction of pH-Dependent Drug-Drug Interactions with Acid-Reducing Agents: a Comparison with Physiologically Based Pharmacokinetic Modeling.

Authors:  Andy Z X Zhu; Ming-Chih David Ho; Christopher K Gemski; Bei-Ching Chuang; Mingxiang Liao; Cindy Q Xia
Journal:  AAPS J       Date:  2016-09-06       Impact factor: 4.009

Review 9.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 10.  Omeprazole drug interaction studies.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.